In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Five Prime Therapeutics, Inc.

https://fiveprime.gcs-web.com/

Latest From Five Prime Therapeutics, Inc.

Amgen Builds Out Antibody Interests With $2.5bn Teneobio Buy

Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.

Companies M & A

Amgen CEO Shines Light On Opportunities For Accelerated Drug Pathways

Amgen CEO Robert Bradway spotlights opportunities to up the tempo of drug discovery and development, drawing from the success of COVID-19 vaccines, and touches on the company's breakthrough treatment Lumakras and efforts in gastric cancer.

Coronavirus COVID-19 Asia Pacific

Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab

Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.

ASCO Cancer

Amgen Ropes Second M&A Deal Of 2021 In Rodeo Buyout

Deal snapshot: Rodeo’s preclinical work in modulating the 15-PDGH enzyme may yield novel regenerative therapies for inflammation, Amgen says, including GI and post-bone marrow transplant indications.

M & A Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Amgen, Inc.
UsernamePublicRestriction

Register